Filtered By:
Vaccination: Shingles (Herpes Zoster) Vaccine

This page shows you your search results in order of date. This is page number 18.

Order by Relevance | Date

Total 272 results found since Jan 2013.

Patients most in need of the vaccine against shingles don't get it 
People at the highest risk of shingles are those with immunosuppressive conditions -- such as HIV -- but they are not entitled to vaccination due to safety concerns, suggests research. Researchers say alternative strategies are needed to reduce the risk of shingles among these patient groups. Shingles is a common disease among older individuals which causes an acute painful rash and can lead to a complication resulting in pain lasting from months to years that can significantly impair a person's quality of life.
Source: ScienceDaily Headlines - May 13, 2014 Category: Science Source Type: news

French National Health Authority recommends routine vaccination with Zostavax® to protect seniors against shingles
The French National High Council for Public Health (HCSP) has recommended routine shingles vaccination for seniors from 65 to 74 years of age. In addition, during the first year a catch-up will be proposed to 75-79 year-olds[1].The recommendation acknowledges the heavy burden of shingles and its often-associated condition, long-lasting pain called post-herpetic neuralgia. The High Council recognizes the significant scientific evidence that vaccination is the only health option that prevents both incidence and severity of disease.
Source: Health News from Medical News Today - December 19, 2013 Category: Consumer Health News Tags: Infectious Diseases / Bacteria / Viruses Source Type: news

Live Attenuated Varicella-Zoster Vaccine in Hematopoietic Stem Cell Transplantation Recipients
We report our experience with using a single dose of VZV vaccine in 110 adult autologous and allogeneic HSCT recipients who were about 2 years after transplantation, free of graft-versus-host disease, and not receiving immunosuppression. One hundred eight vaccine recipients (98.2%) had no clinically apparent adverse events with a median follow-up period of 9.5 months (interquartile range, 6 to 16; range, 2 to 28). Two vaccine recipients (1.8%) developed a skin rash (one zoster-like rash with associated pain, one varicella-like) within 42 days post-vaccination that resolved with antiviral therapy. We could not confirm if...
Source: Biology of Blood and Marrow Transplantation - November 25, 2013 Category: Hematology Authors: Nicolas C. Issa, Francisco M. Marty, Houry Leblebjian, Alicia Galar, Margaret M. Shea, Joseph H. Antin, Robert J. Soiffer, Lindsey R. Baden Tags: Brief Articles Source Type: research

A case of meningitis due to varicella zoster virus reactivation in an immunocompetent child
Conclusion: VZV reactivation can also lead to various neurological complications in immunocompetent children. Prompt therapy with acyclovir and the integrity of the immune system are important in conditioning outcome, but other currently unknown factors probably also play a role.
Source: Italian Journal of Pediatrics - November 13, 2013 Category: Pediatrics Authors: Susanna EspositoSamantha BosisRaffaella PinzaniLaura MorlacchiLaura SenatoreNicola Principi Source Type: research

Should we get over our phobia of vaccines and act against chicken pox?
Charities are calling for a shingles vaccine, to help thousands of people who develop the rash manage the pain    
Source: Telegraph Health - November 6, 2013 Category: Consumer Health News Source Type: news

Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany
Conclusions: According to our evaluation, HZ-vaccination is expected to avoid HZ/PHN-cases and gain QALYs to higher costs. However, the vaccine price had the highest impact on the ICERs. Among different scenarios, targeting individuals aged 60 years seems to represent the most cost-effective vaccination-strategy.
Source: BMC Health Services Research - September 26, 2013 Category: Journals (General) Authors: Bernhard UltschFelix WeidemannThomas ReinholdAnette SiedlerGérard KrauseOle Wichmann Source Type: research

Vaccination of older adults against herpes zoster is safe and effective
Commentary on: Gagliardi AM, Gomes Silva BN, Torloni MR, et al.. Vaccines for preventing herpes zoster in older adults. Cochrane Database Syst Rev 2012;10:CD008858. Context The problem addressed by this study is that older individuals, for example, those over 60 years of age, are more likely to develop herpes zoster (HZ) than younger people. Older adults are far more likely to develop severe complications of HZ, especially postherpetic neuralgia (PHN). Methods Gagliardi and colleagues reviewed eight randomised controlled trials (RCTs) involving 52 269 participants. Findings By focusing on RCTs and assessing the ...
Source: Evidence-Based Medicine - September 19, 2013 Category: Internal Medicine Authors: Tyring, S. K. Tags: Clinical trials (epidemiology), Immunology (including allergy), Vaccination / immunisation, Neuromuscular disease, Pain (neurology), Peripheral nerve disease, Dermatology, Ethics Online articles Source Type: research

Vaccination against and treatment of acute herpes zoster for prevention of post-herpetic neuralgia.
Abstract Zostavax (zoster vaccine) is a 1-dose, high-potency, live, attenuated varicella zoster virus (VZV) vaccine that boosts VZV-specific cell-mediated immunity (CMI), and this is its presumed mechanism of action. Other strategies focus on preventing the major complication of HZ, post-herpetic neuralgia (PHN). Evidence that the vaccine is effective in older patients comes from the pivotal Shingles Prevention Study. That study demonstrated that HZ vaccine significantly reduced morbidity due to HZ and PHN in older patients. However, the duration of efficacy beyond 5 years after vaccination remains unclear. The L...
Source: Herpes - September 7, 2013 Category: Infectious Diseases Authors: Kanbayashi Y, Hosokawa T Tags: Curr Pain Headache Rep Source Type: research

Advances in the treatment of varicella-zoster virus infections.
Abstract Varicella-zoster virus (VZV) causes two distinct diseases, varicella (chickenpox) and shingles (herpes zoster). Chickenpox occurs subsequent to primary infection, while herpes zoster (usually associated with aging and immunosuppression) appears as a consequence of reactivation of latent virus. The major complication of shingles is postherpetic neuralgia. Vaccination strategies to prevent varicella or shingles and the current status of antivirals against VZV will be discussed in this chapter. Varivax®, a live-attenuated vaccine, is available for pediatric varicella. Zostavax® is used to boost VZV-specifi...
Source: Advances in Pharmacology - July 29, 2013 Category: Drugs & Pharmacology Authors: Andrei G, Snoeck R Tags: Adv Pharmacol Source Type: research

Six ways Big Pharma manipulates consumers - Salon
This article originally appeared on AlterNet. The blockbuster pill profit party is over for Big Pharma. Bestselling pills like Lipitor, Seroquel, Zyprexa, Singular and Concerta have gone off patent and sites which their ads sustained are withering on the vine. WebMD, for example, the voice of Pharma on the Web, with a former Pfizer exec serving as CEO, announced it would cut 250 positions in December. But don’t worry, Wall Street. Pharma isn’t going to deliver disappointing earnings just because it has little or no new drugs coming online and has failed at the very reason for its existence. Here are six new Pharma ma...
Source: PharmaGossip - April 28, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs

Neuropathic pain--a management update.
This article summaries the diagnosis and management of four common neuropathic pain presentations. DISCUSSION: A validated diagnostic screening tool can help identify patients with neuropathic pain. A systematic approach to clinical assessment and investigation will clarify the diagnosis. Good glycaemic control is important in the prevention and management of diabetic polyneuropathy; management options include antidepressants, gabapentinoids and controlled release opioids. Pain that lasts for more than 3 months after the onset of a herpes zoster infection is called 'postherpetic neuralgia'; management options include ...
Source: Australian Family Physician - March 1, 2013 Category: Primary Care Authors: Votrubec M, Thong I Tags: Aust Fam Physician Source Type: research

Varicella-Zoster Viruses Associated with Post-Herpetic Neuralgia Induce Sodium Current Density Increases in the ND7-23 Nav-1.8 Neuroblastoma Cell Line.
Abstract Post-herpetic neuralgia (PHN) is the most significant complication of herpes zoster caused by reactivation of latent Varicella-Zoster virus (VZV). We undertook a heterologous infection in vitro study to determine whether PHN-associated VZV isolates induce changes in sodium ion channel currents known to be associated with neuropathic pain. Twenty VZV isolates were studied blind from 11 PHN and 9 non-PHN subjects. Viruses were propagated in the MeWo cell line from which cell-free virus was harvested and applied to the ND7/23-Nav1.8 rat DRG x mouse neuroblastoma hybrid cell line which showed constitutive exp...
Source: Herpes - February 11, 2013 Category: Infectious Diseases Authors: Kennedy PG, Montague P, Scott F, Grinfeld E, Ashrafi GH, Breuer J, Rowan EG Tags: PLoS One Source Type: research

The Fear
When I was 14, my immune system started down its deep,dark path toward permanent dysfunction. It started with a bump,a small red itchy bump that turned into dozens & dozens of bumps in a raised rash that marched up my left arm, across the left side of my chest,down my left armpit & across my back. And then those bumps swelled up,with a yellowish disgusting gunk..to the point of bursting. At that point,convinced that I had cancer, I told my parents & they took me to the doctor.The diagnosis was immeadiete & straightforward."You have the shingles."Isn't that something older people get? Well,yes, but anyone who has had the go...
Source: The D-Log Cabin - January 24, 2013 Category: Diabetes Authors: HVS Source Type: blogs

Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands.
CONCLUSION: Vaccination against HZ might be cost-effective for ages ranging from 60 to 75 when a threshold of €50,000 per QALY gained would be used, at €20,000 per QALY this might not be the case. Additional information on the duration of vaccine-protection is needed to further optimize cost-effectiveness estimations. PMID: 23306360 [PubMed - as supplied by publisher]
Source: Vaccine - January 8, 2013 Category: Allergy & Immunology Authors: de Boer PT, Pouwels KB, Cox JM, Hak E, Wilschut JC, Postma MJ Tags: Vaccine Source Type: research